Breaking News Instant updates and real-time market news.

TSLA

Tesla

$325.89

6.32 (1.98%)

, TEVA

Teva

09:15
08/03/17
08/03
09:15
08/03/17
09:15

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Tesla (TSLA), up 6%... Electro Scientific (ESIO), up 26.5%... SolarEdge (SEDG), up 19%... Fairmount Santrol (FMSA), up 11%... Take-Two (TTWO), up 12%. DOWN AFTER EARNINGS: Teva (TEVA), down 17%... Yum! Brands (YUM), down 1.5%... CommScope (COMM), down 13%... 3D Systems (DDD), down 10%. ALSO LOWER: Avon Products (AVP), down 8% after reporting earnings and announcing that Sheri McCoy to step down as CEO... Molina Healthcare (MOH), down 8% after reporting earnings and announcing plans to cut 1,500 jobs as part of a restructuring... Agile Therapeutics (AGRX), down 22% after its 5.3M share secondary offering priced at $3.75 per share.

TSLA

Tesla

$325.89

6.32 (1.98%)

TEVA

Teva

YUM

Yum! Brands

AVP

Avon Products

MOH

Molina Healthcare

ESIO

Electro Scientific

$8.48

-0.25 (-2.86%)

SEDG

SolarEdge

$22.85

-0.45 (-1.93%)

FMSA

Fairmount Santrol

TTWO

Take-Two

$79.39

-0.54 (-0.68%)

AGRX

Agile Therapeutics

$4.57

-0.03 (-0.65%)

DDD

3D Systems

  • 03

    Aug

  • 03

    Aug

  • 03

    Aug

  • 03

    Aug

  • 03

    Aug

  • 08

    Aug

  • 10

    Aug

  • 30

    Aug

  • 28

    Sep

  • 02

    Oct

  • 26

    Dec

  • 03

    Aug

TSLA Tesla
$325.89

6.32 (1.98%)

08/03/17
UBSW
08/03/17
NO CHANGE
Target $185
UBSW
Sell
Tesla Model 3 margins look challenging, says UBS
UBS analyst Colin Langan noted Tesla reported Q2 results that beat expectations, but he said the company's capital spending guidance implies more cash burn. Also, its second half margin guidance was worse than he expected, noted Langan, who reiterated his Sell rating and $185 price target on Tesla shares.
08/03/17
BOFA
08/03/17
NO CHANGE
Target $155
BOFA
Underperform
Tesla price target lowered to $155 from $165 at BofA/Merrill
BofA/Merrill analyst John Murphy said Tesla's Q2 results were a bit noisy, but generally above expectations. He said Model 3 ramp volume still remains unclear and expects it to take some time before it reaches any material scale, which could lead to production costs outweighing potential benefits of higher volume operating leverage for an extended time. The analyst expects Tesla will need to raise capital by year-end and believes investor patience will wear thin as further capital raises are net met with improving earnings, cash flow, or returns. Murphy lowered Tesla's price target to $155 from $165 on slightly lower forward estimates and maintains an Underperform rating.
08/03/17
PIPR
08/03/17
NO CHANGE
Target $386
PIPR
Overweight
Tesla price target raised to $386 from $368 at Piper Jaffray
Piper Jaffray analyst Alexander Potter raised his price target for Tesla Motors to $386 following last night's Q2 results. In a research note partially titled "Too Many Good Vibes to Consider Bailing Now," Potter says Tesla's operating metrics are improving. The shares should keep moving higher even though the company is facing its toughest challenge yet with the Model 3 production ramp, Potter writes. It is not wise to "bet against a story with this much momentum," the analyst argues. He reiterates an Overweight rating on Tesla. The stock in premarket trading is up 7%, or $22.30, to $348.19.
08/03/17
JPMS
08/03/17
NO CHANGE
Target $200
JPMS
Underweight
Tesla price target raised to $200 from $190 at JPMorgan
JPMorgan analyst Ryan Brinkman raised his price target for Tesla to $200 saying the company's Q2 results were "modestly better than expected." Tesla, however, guided softer in Q3, with margin expected to "dip below" 20%," Brinkman tells investors in a post-earnings research note. Further, while capex tracked lower in Q2, the company guided higher in the second half, suggesting the quarter's lower spending reflects a mere push-out of expenditures into the back half of the year, the analyst adds. He keeps an Underweight rating on Tesla.
TEVA Teva

07/05/17
OPCO
07/05/17
NO CHANGE
Target $70
OPCO
Outperform
Neurocrine Ingrezza 'holds steady' after competitor data, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Teva's (TEVA) Austedo could become a competitor to Neurocrine's (NBIX) Ingrezza with a PDUFA date for the tardive dyskinesia indication on August 30, 2017. However, the analyst sees Ingrezza as well positioned and reiterates an Outperform rating and $70 price target on Neurocrine's shares. A key factor to follow beyond the short trials will be real-life performance considering the number needed to treat to observe a 50% AIMS improvement was 5 for Austedo and 4 for Ingrezza, he contends.
07/18/17
WELS
07/18/17
NO CHANGE
WELS
Market Perform
Novartis report has cautious read-through for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis' (NVS) Sandoz unit is one of the world's largest generic drug makers and he believes the proper read-through from its report is that the U.S. generic market remains challenging and that investors should remain cautious on the generics space. Maris, who said he would not be surprised to see Mylan (MYL) or Teva (TEVA) weaker following Novartis' report, keeps Market Perform ratings on those two names.
07/13/17
SBSH
07/13/17
NO CHANGE
Target $42
SBSH
Buy
Teva landing Soriot would be 'material positive,' says Citi
Citi analyst Liav Abraham believes Calcalist's report of Teva (TEVA) hiring away AstraZeneca's (AZN) CEO Pascal Soriot has credibility given the "relatively accurate track record" of the Israeli press in the "leaking" of information pertaining to Teva. The news, if confirmed, would be a "material positive" for Teva over the near to medium term, Abraham tells investors in a research note. She believes Soriot would "lend significant credibility" to Teva's turnaround thesis. On the other side, Soriot leaving would increase concerns over the pending outcome of AstraZeneca's MYSTIC trial, which constitutes the dominant near-term driver for the shares, Abraham argues. She has a Buy rating on Teva with a $42 price target. The stock in premarket trading is up 2% to $32.80. AstraZeneca is down 14c to $32.78.
07/13/17
LEER
07/13/17
NO CHANGE
LEER
Outperform
AstraZeneca CEO departure now would have 'terrible' optics, says Leerink
Leerink analyst Seamus Fernandez said the media report that AstraZeneca (AZN) CEO Pascal Soriot may be leaving the company to take over at Teva (TEVA) comes as a "major surprise," adding that while the company would not comment to him on the rumor it also did not outright deny the report. While the news does not appear to be related to the outcome of the MYSTIC trial in non-small cell lung cancer, the optics around such a departure at this would be "terrible" and his loss would be a "clear negative" for AstraZeneca, according to Fernandez, who has an Outperform rating on Astra shares.
YUM Yum! Brands

06/08/17
MZHO
06/08/17
INITIATION
Target $74
MZHO
Neutral
Yum! Brands initiated with a Neutral at Mizuho
Mizuho analyst Jeremy Scott initiated Yum! Brands with a Neutral and a $74 price target.
05/16/17
05/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AIG (AIG) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Kai Pan citing the "strong" new Chief Executive Officer and attractive valuation. 2. Yum! Brands (YUM) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's decision to refranchise an additional 5% of its stores and institute additional cost cutting measures as reasons for the upgrade. 3. Dr Pepper Snapple (DPS) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying the company's organic sales growth is accelerating driven by an improved competitive outlook as Coca Cola (KO) and Pepsi (PEP) focus on using cash flow from the U.S. carbonated soft drink segment in high growth areas. 4. Regal Entertainment (RGC) upgraded to Buy from Hold at Loop Capital with analyst David Millerciting recent weakness in shares and has confidence the company will pay a special dividend to shareholders around the fourth quarter or in the first half of 2018. 5. Vipshop (VIPS) upgraded to Overweight from Neutral at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/16/17
ARGS
05/16/17
UPGRADE
ARGS
Buy
Yum! Brands upgraded on refranchising, cost cutting at Argus
As noted earlier, Argus upgraded Yum! to Buy from Hold. Analyst John Staszak cited the company's decision to refranchise an additional 5% of its stores and institute additional cost cutting measures as reasons for the upgrade. He expects the company's 2017 and 2018 EPS to beat expectations. Target $80.
05/16/17
ARGS
05/16/17
UPGRADE
ARGS
Buy
Yum! Brands upgraded to Buy from Hold at Argus
AVP Avon Products

10/21/16
SBSH
10/21/16
NO CHANGE
Target $8
SBSH
Buy
Avon Products price target raised to $8 from $6 at Citi
Citi analyst Wendy Nicholson raised her price target for Avon Products to $8 saying the shares are now more "investable." Debt refinancing has allayed bankruptcy concerns while an investment by Cerberus has boosted confidence in management, Nicholson tells investors in a research note. The analyst keeps a Buy rating on the shares.
07/06/17
DADA
07/06/17
INITIATION
Target $4.25
DADA
Neutral
Avon Products initiated with a Neutral at DA Davidson
DA Davidson analyst Linda Bolton Weiser initiated Avon Products with a Neutral and a $4.25 price target saying she does not see a change in the "status quo" to drive valuation higher near-term.
10/03/16
PIPR
10/03/16
NO CHANGE
PIPR
Chinese tax changes modestly positive for cosmetics makers, says Piper Jaffray
Piper Jaffray analyst Stephanie Wissink noted that the Chinese Ministry of Finance has reduced or eliminated the consumption tax on all cosmetic products as of October 1 to stimulate demand and growth, which she views as a modest positive for Estee Lauder (EL), Avon Products (AVP) and Coty (COTY). Of the three, Estee Lauder has the highest exposure to China, which makes up about 10% of its annual revenues, Wissink added.
MOH Molina Healthcare

07/25/17
LEER
07/25/17
NO CHANGE
Target $80
LEER
Outperform
Leerink remains bullish on Molina Healthcare after job cut announcement
Leerink analyst Ana Gupte continues to have "strong conviction" on Molina Healthcare and reiterates an Outperform rating and a $80 price target after the company's announcement from its interim CEO and CFO Joseph White on the elimination of 1,400 jobs, or 10% of its corporate and health plan workforce. The analyst estimates this could expand margins by over 50 bps or offer 50% net margin expansion and get the company by the end of September to the low end of the stated target of 1.5%-2% net margins.
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
06/14/17
LEER
06/14/17
NO CHANGE
Target $80
LEER
Outperform
Molina Healthcare price target raised to $80 from $70 at Leerink
Leerink analyst Ana Gupte raised her price target for Molina Healthcare shares to $80 and remains "bullish" on the name after a call with CFO and interim CEO Joseph White. The analyst says White aligned with her view that the upcoming re-procurement of State Medicaid contracts "does not pose meaningful downside risk." Further, she learned the CEO search is making good progress with an "attractive slate" of senior executives with Managed Care experience. The analyst keeps an Outperform rating on Molina.
ESIO Electro Scientific
$8.48

-0.25 (-2.86%)

02/27/17
LSCM
02/27/17
INITIATION
Target $7.5
LSCM
Buy
Electro Scientific initiated with a Buy at Lake Street
Lake Street analyst Jaeson Schmidt started Electro Scientific with a Buy rating and $7.50 price target.
08/03/17
08/03/17
UPGRADE
Target $12

Buy
Electro Scientific upgraded to Buy at Needham
As previously reported, Needham analyst James Ricchiuti upgraded Electro Scientific to Buy from Hold, with a $12 price target, after the company reported much better than expected Q1 results, highlighted by another "outstanding" bookings quarter.
02/27/17
02/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Laureate Education (LAUR) initiated with a Buy at Stifel, with an Outperform at Macquarie, with an Overweight at Morgan Stanley, with an Overweight at Piper Jaffray and with an Equal Weight at Barclays. 2. Invitation Homes (INVH) initiated with a Buy at BofA Merrill Lynch, with a Buy at Deutsche Bank, with an Outperform at Credit Suisse, with an Overweight at JPMorgan, with an Overweight at Morgan Stanley and with a Neutral at Goldman Sachs. 3. Electro Scientific (ESIO) initiated with a Buy at Lake Street. 4. Heron Therapeutics (HRTX) initiated with a Buy at Needham. 5. American Homes 4 Rent (AMH) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/03/17
NEED
08/03/17
UPGRADE
NEED
Buy
Electro Scientific upgraded to Buy from Hold at Needham
SEDG SolarEdge
$22.85

-0.45 (-1.93%)

08/03/17
JMPS
08/03/17
NO CHANGE
JMPS
SolarEdge price target raised to $40 from $25 at JMP Securities
JMP Securities analyst Joseph Oasha rasied his price target on SolarEdge after the company reported much better than expected Q2 results. Calling the results "very strong," Osha says that the company is gaining market share quickly. He thinks its competitors will have trouble keeping up with its R&D advances going forward, and he keeps an Outperform rating on the shares.
08/03/17
OPCO
08/03/17
NO CHANGE
Target $32
OPCO
Outperform
SolarEdge price target raised to $32 from $25 at Oppenheimer
Oppenheimer analyst Colin Rusch raised his price target for SolarEdge to $32 from $25 after the company posted results ahead of consensus while guiding Q3 revenue above estimates. The analyst reiterates an Outperform rating on the shares.
07/28/17
ADAM
07/28/17
NO CHANGE
Target $25
ADAM
Buy
SolarEdge price target raised to $25 from $19 at Canaccord
Canaccord analyst John Quealy raised his price target on SolarEdge to $25 from $19 as the broader solar markets are experiencing the typical boom/bust dynamics. The company has differentiated power conversion and control offerings, offering a clear path toward secular profit improvement, said Quealy, who reiterated his Buy rating on SolarEdge shares.
08/03/17
ADAM
08/03/17
NO CHANGE
Target $30
ADAM
Buy
SolarEdge price target raised to $30 from $25 at Canaccord
Canaccord analyst John Quealy raised his price target on SolarEdge to $30 from $25 following Q2 results. The analyst said SolarEdge's differentiated power conversion and control offerings provide a clearer path toward secular profit improvement and he remains a buyer as the company delivers what investors want - big revenues and margin upside. Quealy reiterated his Buy rating on SolarEdge shares.
FMSA Fairmount Santrol

07/20/17
GSCO
07/20/17
DOWNGRADE
Target $2
GSCO
Sell
Fairmount Santrol downgraded to Sell from Neutral at Goldman Sachs
Goldman analyst Waqar Saed downgraded Fairmount Santrol to Sell saying its competitive positioning is weakening as the customer base of its Wedron plant shift away from Texas and said its weak balance sheet is a "major negative. The analyst cut his price target to $2 from $11 on Fairmount Santrol shares.
07/20/17
FBCO
07/20/17
DOWNGRADE
Target $4
FBCO
Neutral
Fairmount Santrol downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst James Wicklund downgraded Fairmount Santrol to Neutral from Outperform, citing the rapid and significant continued announcements of additional Texas sand available for the fastest growing basins of the Permian, the Eagle Ford, and the Scoop/Stack. The impact of this expansion in Texas regional sand lowers the industry's cost curve and puts non-Texas sand at an economic disadvantage, he adds. The analyst also lowered his price target on the shares to $4 from $12.
07/20/17
07/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying he believes the stock's upside drivers are more limited over the next year. 2. Rite Aid (RAD) downgraded to Neutral from Buy at Mizuho. 3. Fairmount Santrol (FMSA) was downgraded to Sell from Neutral at Goldman Sachs and to Neutral from Outperform at Credit Suisse. 4. New Relic (NEWR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Sanjit Singh saying shares are up 71% year-to-date and valuation captures solid fundamentals but sees fewer catalysts. 5. Smart Sand (SND) downgraded to Neutral from Outperform at Credit Suisse with analyst James Wicklund saying the regional sand volumes capacity is expanding much faster than had been expected. This drives lower pricing and demand for non-Texas mines, he adds. The analyst also lowered his price target on the shares to $8.50 from $20. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/17
HOWW
06/28/17
DOWNGRADE
HOWW
Sector Perform
Fairmount Santrol downgraded to Sector Perform at Scotia Howard Weil
TTWO Take-Two
$79.39

-0.54 (-0.68%)

07/20/17
MKMP
07/20/17
NO CHANGE
MKMP
Take-Two should be bought at current levels, says MKM Partners
MKM Partners analyst Eric Handler recommends buying Take-Two into strength as the analyst says that the stock remains "very attractive" and still has multiple positive catalysts, including additional information about RedDead Redemption 2 and "the likelihood of upward estimate revisions." He expects the company's Q1 results to beat expectations.
08/03/17
BNCH
08/03/17
NO CHANGE
Target $100
BNCH
Buy
Take-Two price target raised to $100 from $85 at Benchmark
Benchmark analyst Mike Hickey thinks Take-Two has a compelling FY19 growth profile, citing Red Dead Redemption 2 and future content for GTA Online, and he believes the company could see acquisition consideration. He raised his price target on Take-Two shares to $100 from $85 and keeps a Buy rating on the stock following the company's Q1 report.
08/03/17
PIPR
08/03/17
NO CHANGE
Target $100
PIPR
Overweight
Take-Two price target raised to $100 from $83 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for Take-Two Interactive to $100 saying the company reported a "very strong" quarter. The analyst reiterates an Overweight rating on the shares.
08/03/17
OPCO
08/03/17
NO CHANGE
Target $93
OPCO
Outperform
Take-Two price target raised to $93 from $85 at Oppenheimer
Oppenheimer analyst Andrew Uerkwitz raised his price target for Take-Two to $93 from $85 following quarterly results and as he sees annual earnings volatility decreasing, a growing mobile business, continued secular tailwinds, and an upcoming mega-year. The analyst reiterates an Outperform rating on the shares.
AGRX Agile Therapeutics
$4.57

-0.03 (-0.65%)

07/19/17
HCWC
07/19/17
INITIATION
Target $10
HCWC
Buy
Agile Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Agile Therapeutics with a Buy rating and $10 price target. The stock is "significantly undervalued" assuming Twirla can get FDA approval, Davis tells investors in a research note. Agile is a one product story "potentially very close" to finally getting its combination hormonal contraceptive transdermal patch to market, the analyst adds.
01/27/17
RBCM
01/27/17
NO CHANGE
RBCM
Agile Therapeutics shares undervalued, says RBC Capital
After meeting with Agile Therapeutics' management, RBC Capital analyst Randall Stanicky believes that the stock does not "appropriately price in" a possible rally in the shares. The analyst says that the company has a "solid case" for FDA approval of its lead contraceptive patch, Twirla, He adds that Agile could be acquired if the patch is approved in Q4, in-line with the company's target. The analyst keeps an $8 price target and an Outperform rating on the shares. .
07/19/17
07/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tyson Foods (TSN) reinstated with a Neutral at Credit Suisse. 2. Bob Evans (BOBE) initiated with a Buy at Berenberg. 3. Quanex (NX) coverage assumed with an Outperform at Wedbush. 4. Agile Therapeutics (AGRX) initiated with a Buy at H.C. Wainwright. 5. Caesars (CZR) re-initiated with an Outperform at Imperial Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/17
03/06/17
NO CHANGE

FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
DDD 3D Systems

08/03/17
PIPR
08/03/17
NO CHANGE
Target $14
PIPR
Underweight
3D Systems reported disappointing results, says Piper Jaffray
Piper Jaffray analyst Troy Jensen says 3D Systems (DDD) last night reported disappointing results with weak printer sales being the primary factor in the revenue miss. The weak printer sales are directly correlated with increased competition from HP Inc. (HPQ), General Electric (GE) and others attacking 3D Systems' key product lines, Jensen tells investors in a post-earnings research note. He sees the company's second half of 2017 as "incrementally more challenging" and believes the stock's a "significant premium" to 3D printing peers is unwarranted. The analyst reiterates an Underweight rating on 3D Systems with a $14 price target.
07/24/17
LOOP
07/24/17
INITIATION
Target $18
LOOP
Hold
3D Systems initiated with a Hold at Loop Capital
Loop Capital analyst Ananda Baruah started 3D Systems with a Hold rating and $18 price target.
07/13/17
07/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. HP Inc. (HPQ), 3D Systems (DDD), and Stratasys (SSYS) were initiated with a Neutral at Susquehanna. 2. Danaher (DHR) initiated with a Market Perform at Wells Fargo. 3. E-Trade (ETFC) and TD Ameritrade (AMTD) were initiated with a Buy at Rosenblatt, while Charles Schwab (SCHW) was initiated with a Neutral. 4. C&J Energy Services (CJ) initiated with a Buy at Jefferies. 5. BIO-key (BKYI) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/17
PIPR
07/19/17
NO CHANGE
PIPR
Underweight
Piper checks show 3D Systems had another challenging quarter
Piper Jaffray analyst Troy Jensen says feedback from 63 3D printing resellers indicates the demand uptick in Q1 has sustained in Q2 with system sales relatively in line with expectations and strong material sales helping profitability. Stratasys' (SSYS) results were "relatively balanced," but 3D Systems' (DDD) resellers expressed another challenging quarter for system demand, Jensen tells investors in a research note. The weakness at 3D Systems is directly correlated with the launch of HP's (HPQ) Jet Fusion printer, the analyst contends. He believes now is the time for investors to revisit the 3D printing space, preferring shares of Stratasys, Materialise (MTLS), Proto Labs (PRLB) and voxeljet (VJET). Jensen recommends avoiding shares of 3D Systems at current levels.

TODAY'S FREE FLY STORIES

MTP

Midatech Pharma

$0.98

-0.0099 (-1.00%)

04:55
02/19/18
02/19
04:55
02/19/18
04:55
Conference/Events
Midatech Pharma management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 27

    Feb

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/19/18
02/19
04:55
02/19/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 07

    Jun

  • 13

    Nov

03:05
02/19/18
02/19
03:05
02/19/18
03:05
General news
FX Update: The dollar traded generally firmer »

FX Update: The dollar…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/18/18
02/18
04:55
02/18/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MRVL

Marvell

$22.68

-0.06 (-0.26%)

, CAVM

Cavium

$87.16

-0.09 (-0.10%)

14:55
02/17/18
02/17
14:55
02/17/18
14:55
Conference/Events
Cavium to host special shareholder meeting »

Special Shareholder…

MRVL

Marvell

$22.68

-0.06 (-0.26%)

CAVM

Cavium

$87.16

-0.09 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 08

    Mar

CAVM

Cavium

$87.16

-0.09 (-0.10%)

, MRVL

Marvell

$22.68

-0.06 (-0.26%)

14:51
02/17/18
02/17
14:51
02/17/18
14:51
Conference/Events
Marvell to host special shareholder meeting »

Special Shareholder…

CAVM

Cavium

$87.16

-0.09 (-0.10%)

MRVL

Marvell

$22.68

-0.06 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

DEL

Deltic Timber

$98.45

1.77 (1.83%)

, PCH

Potlatch

$54.75

0.75 (1.39%)

14:45
02/17/18
02/17
14:45
02/17/18
14:45
Conference/Events
Potlatch to host special shareholder meeting »

Special Shareholder…

DEL

Deltic Timber

$98.45

1.77 (1.83%)

PCH

Potlatch

$54.75

0.75 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

PCH

Potlatch

$54.75

0.75 (1.39%)

, DEL

Deltic Timber

$98.45

1.77 (1.83%)

14:42
02/17/18
02/17
14:42
02/17/18
14:42
Conference/Events
Deltic Timber to host special shareholder meeting »

Special shareholder…

PCH

Potlatch

$54.75

0.75 (1.39%)

DEL

Deltic Timber

$98.45

1.77 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$20.42

0.67 (3.39%)

09:31
02/17/18
02/17
09:31
02/17/18
09:31
Periodicals
Snap CEO sold $50M in stock this week, Recode reports »

Snap CEO Evan Spiegel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

, MPSYY

MorphoSys

$46.29

1.29 (2.87%)

09:27
02/17/18
02/17
09:27
02/17/18
09:27
Hot Stocks
Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD »

Galapagos NV (GLPG) and…

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

MPSYY

MorphoSys

$46.29

1.29 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$360.53

-0.47 (-0.13%)

09:22
02/17/18
02/17
09:22
02/17/18
09:22
Hot Stocks
Lockheed Martin receives Freedom-variant FFG conceptual design contract »

The U.S. Navy awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

  • 30

    May

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

, UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

09:11
02/17/18
02/17
09:11
02/17/18
09:11
Periodicals
Bears, bulls battle over Under Armour, Barron's says »

In a follow-up story,…

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$2.24

0.12 (5.66%)

09:04
02/17/18
02/17
09:04
02/17/18
09:04
Periodicals
Hovnanian stock too cheap to ignore, Barron's says »

Hovnanian Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

, JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

09:00
02/17/18
02/17
09:00
02/17/18
09:00
Periodicals
JPMorgan, Walmart cash flow yields exceed dividend yields, Barron's says »

The cash flow yields of…

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

, GOOG

Alphabet

$1,094.80

5.28 (0.48%)

08:56
02/17/18
02/17
08:56
02/17/18
08:56
Periodicals
Alphabet, Citi well positioned for later stages of market rally, Barron's says »

It is time for investors…

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 18

    Mar

  • 28

    Mar

  • 29

    Mar

  • 30

    May

GE

General Electric

$15.05

0.2 (1.35%)

08:48
02/17/18
02/17
08:48
02/17/18
08:48
Periodicals
General Electric stock could drop another 10%, Barron's says »

General Electric lost $6B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

, VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

08:32
02/17/18
02/17
08:32
02/17/18
08:32
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

PWR

Quanta Services

$35.07

0.24 (0.69%)

EXP

Eagle Materials

$102.75

-3.83 (-3.59%)

FLR

Fluor

$57.63

-0.22 (-0.38%)

USCR

U.S. Concrete

$78.00

-1.4 (-1.76%)

ACM

Aecom

$35.36

0.08 (0.23%)

CBI

CB&I

$18.71

0.04 (0.21%)

GVA

Granite Construction

$60.36

2.69 (4.66%)

CAT

Caterpillar

$156.29

-3.69 (-2.31%)

MLM

Martin Marietta

$216.25

-6.34 (-2.85%)

V

Visa

$121.85

-0.43 (-0.35%)

AA

Alcoa

$47.36

-0.21 (-0.44%)

ARNC

Arconic

$25.36

0.14 (0.56%)

CENX

Century Aluminum

$24.12

1.85 (8.31%)

X

U.S. Steel

$44.75

5.76 (14.77%)

STLD

Steel Dynamics

$49.40

2.26 (4.79%)

AKS

AK Steel

$5.96

0.72 (13.74%)

CLF

Cleveland-Cliffs

$7.92

0.55 (7.46%)

NUE

Nucor

$68.54

2.96 (4.51%)

MT

ArcelorMittal

$36.48

1.19 (3.37%)

TKR

Timken

$45.00

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

  • 23

    May

  • 30

    May

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
Cambridge Healthtech Institute to hold a conference »

Molecular Med Tri-Con…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MIDD

Middleby

$135.00

1.94 (1.46%)

18:01
02/16/18
02/16
18:01
02/16/18
18:01
Hot Stocks
Middleby acquires Hinds-Bock Corporation, terms not disclosed »

Middleby announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.14

0.14 (0.38%)

, TWX

Time Warner

$95.37

0.38 (0.40%)

17:37
02/16/18
02/16
17:37
02/16/18
17:37
Periodicals
Breaking Periodicals news story on AT&T, Time Warner »

Judge says to rule on …

T

AT&T

$37.14

0.14 (0.38%)

TWX

Time Warner

$95.37

0.38 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

CARS

Cars.com

$29.27

0.33 (1.14%)

17:31
02/16/18
02/16
17:31
02/16/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Cars.com »

Starboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONTX

Onconova

$1.07

0.01 (0.94%)

17:29
02/16/18
02/16
17:29
02/16/18
17:29
Hot Stocks
683 Capital reports 21.8% stake in Onconova, says shares undervalued »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$224.19

-1.21 (-0.54%)

17:26
02/16/18
02/16
17:26
02/16/18
17:26
Hot Stocks
General Dynamics awarded $148.9M government contract modification »

General Dynamics Land…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRS

Antares Pharma

$2.39

0.04 (1.70%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Breaking Hot Stocks news story on Antares Pharma »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.